Valneva SE (EPA: VLA)
France
· Delayed Price · Currency is EUR 2.122
+0.050 (2.41%)
Jan 20, 2025, 5:35 PM CET
Valneva SE Revenue
Valneva SE had revenue of 45.82M EUR in the quarter ending September 30, 2024, with 20.36% growth. This brings the company's revenue in the last twelve months to 158.54M, down -28.98% year-over-year. In the year 2023, Valneva SE had annual revenue of 153.71M, down -57.46%.
Revenue (ttm)
158.54M
Revenue Growth
-28.98%
P/S Ratio
1.84
Revenue / Employee
234.52K
Employees
676
Market Cap
344.55M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 153.71M | -207.59M | -57.46% |
| Dec 31, 2022 | 361.30M | 13.22M | 3.80% |
| Dec 31, 2021 | 348.09M | 237.76M | 215.52% |
| Dec 31, 2020 | 110.32M | -15.88M | -12.58% |
| Dec 31, 2019 | 126.20M | 13.16M | 11.64% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sanofi | 48.45B |
| EssilorLuxottica Société anonyme | 25.83B |
| Sartorius Stedim Biotech | 2.74B |
| bioMérieux | 3.81B |
| Ipsen | 3.44B |
| Eurofins Scientific SE | 6.72B |
| Virbac | 1.34B |
| Ramsay Générale de Santé | 5.01B |
Valneva SE News
- 14 days ago - Valneva to Meet with Investors during the J.P. Morgan Healthcare Conference - GlobeNewsWire
- 4 weeks ago - Valneva Successfully Expands Access to Asia for its Chikungunya Vaccine with Serum Institute of India - GlobeNewsWire
- 6 weeks ago - Valneva Announces Peer-Reviewed Publication on the Global Health and Economic Burden of Chikungunya in The British Medical Journal - GlobeNewsWire
- 6 weeks ago - Valneva's Chikungunya Shot Shows Strong, Long-Lasting Antibody Persistence At Three Years, Comparable In Older And Younger Adults - Benzinga
- 7 weeks ago - Valneva Reports Positive Three-Year Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ® - GlobeNewsWire
- 7 weeks ago - Valneva Submits Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to the U.S. FDA - GlobeNewsWire
- 2 months ago - European And US Vaccine Stocks Are Under Pressure - Here's WHy - Benzinga
- 2 months ago - Valneva and LimmaTech Announce First Vaccination in Phase 2b Human Challenge Study of Tetravalent Shigella Vaccine Candidate S4V2 - GlobeNewsWire